South San Francisco Biotech Business Locations

South San Francisco, CA  August 1, 2018 Submitted by Chris Gallagher

EDITORS NOTE: Thanks to Chris Gallagher sending us this article in San Francisco Business Times, written by  – Reporter, San Francisco Business Times Updated

One Tower Place, South San Francisco

Status: The 12-story south building of the Genesis-South San Francisco complex is fully leased, including 15,000 square feet to GigaGen, 32,355 square feet to Corbion Biotech and nearly 100,000 square feet to Achaogen Inc., which moved its headquarters from the tip of Shoreline Court.

Space: 340,000 square feet

Landlord: Phase 3 Real Estate Partners


Two Tower Place, South San Francisco

Status: One full floor and two partial floors are leased to unidentified companies in Genesis’ 21-story north tower, which is expected to complete construction in October.

Space: 375,000 square feet

Landlord: Phase 3 Real Estate Partners


494 Forbes Blvd., South San Francisco

Status: Two four- to five-story office/R&D buildings plus a parking structure are planned on the 7.48-acre site, but construction hasn’t yet started on a site that was entitled in December 2012.

Space: 326,020 square feet

Landlord: HCP


249-279 E. Grand Ave., South San Francisco

Status: Google-backed Verily Life Sciences took the former Onyx Pharmaceuticals site and is adding a fourth building of about 130,000 square feet that was entitled last October and set for completion in mid-2019.

Space: Overall 540,000 square feet over the four buildings

Landlord: Alexandria Real Estate Equities


328 Roebling Road, South San Francisco

Status: The two-building office and R&D project and subterranean parking over nearly three acres was entitled in late 2012. Construction hasn’t yet started.

Space: 105,536 square feet

Landlord: HCP


213-221 E. Grand Ave., South San Francisco

Status: Drug giant Merck & Co. Inc. will center its West Coast research center in the building on a 6.2-acre site. The fast-moving project, entitled in June 2017, is expected to be ready for occupancy early next year.

Space: 291,000 square feet

Landlord: Alexandria Real Estate Equities


475 Eccles Road

Status: On the back side of its big Gateway of Pacific project, BioMed was entitled two years ago to build two four-story office and R&D structures on the 6.1-acre site.

Space: 262,287 square feet plus a five-level parking structure

Landlord: BioMed


111 Oyster Point Blvd.

Status: Part of the 884,244-square-foot Britannia Cove at Oyster Point project, including seven biotech office and R&D buildings, a hotel, eight-story parking structure and retail, Five Prime Therapeutics earlier this year moved into the new space.

Space: 115,466 square feet

Landlord: HCP


121 Oyster Point Blvd.

Status: AstraZeneca in May formally opened its facility, bringing its MedImmune unit, which had been in Mountain View, into the same building with its respiratory diseases company Pearl Therapeutics and cancer drug developer Acerta Pharma, both of which had offices and labs in Redwood City.

Space: 163,000 square feet

Landlord: HCP


131 Oyster Point Blvd.

Status: Alector, a fast-growing company developing drugs aimed at attacking Alzheimer’s disease by modulating the brain’s immune system, is taking 100,000 square feet on the fourth through sixth floors. The company currently is subleasing about 10,000 square feet from CytomX Therapeutics at 151 Oyster Point.

Space: Total space is 182,000 square feet

Landlord: HCP


161 Oyster Point Blvd.

Status: Less than three years after startup Denali Therapeutics Inc. inked a lease for 38,209 square feet in the first building constructed in the Cove, the now-public and fast-growing neurodegenerative diseases drug developer signed a lease for another Cove building just a few feet away. Denali will move into the entire building, now under construction, early next year.

Space: 148,020 square feet

Landlord: HCP


181 Oyster Point Blvd.

Status: Global Blood Therapeutics has the right of first negotiation on the last Cove building to be constructed, according to its existing lease at 171 Oyster Point. The company says it is exploring its options but hasnÕt signed a lease.

Space: 148,020 square feet

Landlord: HCP


Oyster Point Boulevard and Gateway Boulevard

Status: AbbVie, which is seeking up to a half-million square feet of space in South San Francisco, is rumored to be interested in the first phase of the Gateway of Pacific project that is under construction. The first phase, including a 12-story building for labs and offices and a 50,000-square-foot amenity center, would be ready for move-in early next year.

Space: 1.3 million square feet total

Landlord: BioMed


7000 Marina Blvd., Brisbane

Status: Sangamo Therapeutics looks to move from Richmond to a new headquarters by the end of the year.

Space: 87,700 square feet

Landlord: Marina Boulevard Property LLC


8000 Marina Blvd., Brisbane

Status: Nut allergy drug developer Aimmune Therapeutics leased more space at the site, which it moves into this year.

Space: 14,841 square feet in addition to 26,355 square feet leased since 2015

Landlord: Diamond Marina LLC


3000 and 3500 Marina Blvd., Brisbane

Status: Phase 3 locked up the 8.9-acre site earlier this year from Opus Group and signed Skidmore Owings & Merrill to design a three-building complex.

Space: 445,000 square feet

Landlord: Phase 3


Southeast corner Sierra Point Parkway and Shoreline Court, Brisbane

Status: Initially approved by planners in 2008, HCP submitted building permit applications last year for the first two R&D buildings at a cost of $220 million. Construction starts this year on the overall 22-acre site with delivery late next year.

Space: 215,000 square feet initially; overall, five three- to four-story buildings totaling 616,000 square feet

Landlord: HCP


1000 Marina Blvd., Brisbane

Status: Phase 3 last month bought the six-story building from Meridian for $39.5 million. It is 92 percent occupied, but the developer’s plan is to start converting it by the end of the year into 5,000- to 10,000-square-foot lab suites.

Space: 104,000 square feet

Landlord: Phase 3 Real Estate Partners


Oyster Point and Marina boulevards, South San Francisco

Status: Work on Kilroy Oyster Point, which had been known as The Landing at Oyster Point, started last fall with demolition and infrastructure improvements. Kilroy, which this spring bought the development from a development group led by a China-based developer, initially plans to build three six-story office and R&D buildings. The project has been entitled since March 2011. It eventually will also include a hotel and open space on city-owned land.

Space: 600,000 square feet; potentially 2.25 million square feet

Landlord: Kilroy Realty


500 E. Grand Ave.

Status: Genentech is building an eight-story office and amenities building, entitled in March 2017 with a completion date of late next year.

Space: 160,000 square feet

Developer: Genentech


560 Eccles Ave.

Status: The USDA expects to construct an office building on 3.6 acres of vacant land.

Space: 21,807 square feet

Developer: USDA

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.